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Recent genome-wide descriptions of CpGmethylation patterns in mammalian cells identified many differen-
tially methylated regions (DMRs) located at CpG island ‘‘shores.’’ Feinberg, Daley, and colleagues now report
in Nature Genetics that reconfiguration of these DMRs occurs during induced reprogramming (Doi et al.,
2009).Dynamic regulation of DNA methylation
underlies one of the major mechanisms
of epigenetic memory. A significant pro-
portion of cytosine bases in the mamma-
lian genome are methylated, with the
notable exception of many CpG islands—
regions rich in CpG dinucleotides associ-
ated with around half of all promoters.
Specific examples of regulatedCpG island
methylation have been identified (e.g.,
genomic imprinting), but whether changes
in DNAmethylation around tissue-specific
promoters are a general feature of
development and differentiation has re-
mained unclear. Recent advances in
high-throughput epigenomic technologies
promise to shed new light on this area
(Suzuki and Bird, 2008).
In a new study published recently in
Nature Genetics, Doi et al. (2009)
compare genome-wide maps of CpG
methylation in fibroblasts and their
induced pluripotent stem cell (iPSC) deriv-
atives (Figure 1A; Doi et al., 2009). The
same laboratory recently demonstrated
that liver, spleen, and brain display a large
set of tissue differentially methylated
regions (T-DMRs) (Irizarry et al., 2009).
Unexpectedly, T-DMRs are predomi-
nantly located at CpG island ‘‘shores’’
(Figure 1B), regions of lower CpG density
that lie in close proximity, but often not
within, CpG islands (Irizarry et al., 2009).
These regions are sufficient to distinguish
between specific tissues and are con-
served between human and mouse. Doi
et al. (2009) used the same approach,
termed CHARM (comprehensive high-
throughput arrays for relative methylation)
(Irizarry et al., 2008), to assess CpGmeth-
ylation in fibroblasts and iPSCs. Genomic
DNA was digested with a restriction
enzyme (McrBC) that cuts most methyl-
ated DNA, size fractionated and hybrid-ized to custom-designed genomic tiling
arrays. This method has the advantage
that almost all CpG islands and shores
across the genome can be assessed for
DNA methylation.
Initially, six different fibroblast-iPSC
pairs were compared, and 4401 reprog-
rammingDMRs (R-DMRs) were identified.
70% of the R-DMRs were associated
with CpG island shores. A similar propor-
tion of R-DMRswere hypo- and hyperme-
thylated, and a greater-than-expected
number of these regions were also previ-
ously identified T-DMRs. This observed
overlap suggests that R-DMRs are en-
riched for regions that commonly define
cellular identity. There were other notable
observations. The majority of hypomethy-
lated DMRs were found at genes previ-
ously shown to contain bivalent domains
(chromatin displaying both active H3K4
and repressive H3K27 histone methyla-
tion marks) (Bernstein et al., 2006), and
many were linked to genes with known
binding sites for Oct4, Nanog, and Sox2,
critical transcriptional regulators that
establish pluripotency. It is a long-standing
question whether regions of methylation
serve as cis-acting regulatory elements
with important roles in transcriptional regu-
lation. Although causality is difficult to
address, they did find a correlation with
gene expression levels, suggesting some
functional significance.
To determine whether R-DMRs are
a consistent feature of fibroblast reprog-
ramming, Doi et al. characterized methyl-
ation patterns in three further pairs of
fibroblast and iPSC lines and identified
an 80% overlap with the first set. The
authors also mapped methylation sites in
human embryonic stem cell (ESC) lines,
and reassuringly, iPSCs and ESCs are
remarkably similar, with only a small setCell Stem Cell 5,of DMRs identified between them. How-
ever, given the interest in these cells for
regenerative medicine, it is clearly now
important to characterize these regions
to determine any functionally significant
consequences.
Extensive epigenetic reconfiguration
also occurs during tumorigenesis. This
trend can be seen as hypermethylation
at tumor suppressor loci and global DNA
hypomethylation. The Feinberg laboratory
had also previously identified cancer
DMRs (C-DMRs) when comparing colon
cancer with patient-matched normal
tissue (Irizarry et al., 2009). Remarkably,
16% of the C-DMRs overlap with the set
of R-DMRs and are also located at CpG
island shores. However, the methylation
status of these regions is opposite, with
hypermethylated regions in cancer being
hypomethylated in pluripotent cells and
vice versa. Thus, epigenetic changes
that occur during nuclear reprogramming
to iPSCs seem to target many of the same
shores but the changes are distinct
from those that occur in cancer. It will be
interesting now to compare the status of
R-DMRs in other tumor types such as
glioblastoma, where an apparent ‘‘ESC-
like’’ gene expression signature has
been reported (Ben-Porath et al., 2008).
One difficulty in analyses such as these
is the issue of heterogeneity present
within bulk samples. For both tissue and
cancer DMRs, the population under study
comprises a mixture of phenotypically
diverse cell types, and the resulting profile
is therefore an average value. So it will be
important to identify how DNA methyla-
tion patterns compare across distinct
cell types within a single tissue. Also
clearly of interest will be whether putative
cancer stem cells have distinct patterns of
DNA methylation from their differentiatedDecember 4, 2009 ª2009 Elsevier Inc. 571
Cell Stem Cell
Previewsnontumorigenic progeny.
Heterogeneity in a more
subtle form, namely cell-cell
variation or fluctuations, also
provides a challenge to
studies of pluripotent cells.
For example, even within
overtly undifferentiated ESC
colonies, genes such asStella
have been shown to display
heterogeneity in expression
levels that correlate with their
propensity to differentiate
and specific epigenetic
changes, including DNA
methylation (Hayashi et al.,
2008). Genome-wide methyl-
ation analysis of single cells
will be needed to address
this potentially confounding
factor, which clearly presents
a massive technological chal-
lenge, but with rapid develop-
ments in next generation se-
quencing, this achievement
may not be far away (Clarke
et al., 2009).
The Doi et al. study
provides an important step
toward defining the biological
role of DNA methylation in
pluripotency, lineage com-
mitment, and differentiation.
As with all interesting ad-
vances, more questions are raised than
are answered. When and how are these
specific epigenetic marks laid down
during normal development? If they are
an early event, do they underlie germ layer
restrictions? Will a similar set of R-DMRs
be identified between iPSCs and parental
cell types other than fibroblasts? What is
their status in tissue stem cells, such as
neural stem cells, which are more easily
reprogrammed (Silva et al., 2008)? What
is the status of the R-DMRs in partially re-
programmed prepluripotent cells (Silva
et al., 2008)?
Another major advance in this area was
recently reported in Nature. Whole-ge-
nome assessment of DNA methylation
was performed via the gold standard bi-
sulphite sequencing method to achieve
single-nucleotide resolution of an ESC
methylome (Lister et al., 2009). Unde-
tected by the CHARM method, this
approach identified a large fraction of
non-CpG methylation in ESCs but not
differentiated cells, raising the prospect
of non-CpG ‘‘offshore’’ DMRs also playing
a role in reprogramming and pluripotency.
Non-CpGmethylation was also present in
iPSCs and is largely associated with gene
bodies, including many developmentally
expressed loci. Clearly, interesting times
lie ahead in resolving the significance of
DNA methylation in human
biology and biomedicine.
Finally, we have some maps
to navigate the islands and
shores of the epigenome.
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Figure 1. Differently Methylated Regions Found at CpG Island
Shores Can Discriminate between Different Cell Types, Including
Somatic, Diseased, and Reprogrammed Cells
(A) Differentially methylated regions (DMRs) were previously identified
between different somatic tissues (T-DMRs) and between normal and cancer
cells (C-DMRs). This study compares fibroblasts and reprogrammed iPSCs to
identify reprogramming DMRs (R-DMRs).
(B) Example of a DMR. CpG dinucleotides (lollipops), common targets of DNA
methylation, are distributed throughout the genome and are usually methyl-
ated (blue lollipops). CpG islands (white box), regions rich in CpG dinucleo-
tides, associate with many gene promoters and are usually unmethylated
(yellow lollipops). DMRs are often located at CpG island shores (gray boxes),
regions of close proximity, but not within CpG islands. Shores are enriched
for T-DMRs, C-DMRs, and, as shown here by Doi et al., also for R-DMRs.
Shore DMRs can be hypo- or hypermethylated and some overlap between
the different DMR types.572 Cell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc.
